Display options
Cite
Takaoka R, Soejima Y, Guro S, et al. Model-based meta-analysis of changes in circulatory system physiology in patients with chronic heart failure. CPT Pharmacometrics Syst Pharmacol. 2021;10(9):1081-1091doi: 10.1002/psp4.12676.
Takaoka, R., Soejima, Y., Guro, S., Yoshioka, H., Sato, H., Suzuki, H., & Hisaka, A. (2021). Model-based meta-analysis of changes in circulatory system physiology in patients with chronic heart failure. CPT: pharmacometrics & systems pharmacology, 10(9), 1081-1091. https://doi.org/10.1002/psp4.12676
Takaoka, Ryota, et al. "Model-based meta-analysis of changes in circulatory system physiology in patients with chronic heart failure." CPT: pharmacometrics & systems pharmacology vol. 10,9 (2021): 1081-1091. doi: https://doi.org/10.1002/psp4.12676
Takaoka R, Soejima Y, Guro S, Yoshioka H, Sato H, Suzuki H, Hisaka A. Model-based meta-analysis of changes in circulatory system physiology in patients with chronic heart failure. CPT Pharmacometrics Syst Pharmacol. 2021 Sep;10(9):1081-1091. doi: 10.1002/psp4.12676. Epub 2021 Jul 16. PMID: 34218511; PMCID: PMC8452295.
Copy Download .nbib Format: NLM
Share it on

CPT Pharmacometrics Syst Pharmacol. 2021 Sep;10(9):1081-1091. doi: 10.1002/psp4.12676. Epub 2021 Jul 16.

Model-based meta-analysis of changes in circulatory system physiology in patients with chronic heart failure.

CPT: pharmacometrics & systems pharmacology

Ryota Takaoka, Yukako Soejima, Sayuri Guro, Hideki Yoshioka, Hiromi Sato, Hiroshi Suzuki, Akihiro Hisaka

Affiliations

  1. Department of Pharmacy, The University of Tokyo Hospital, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
  2. Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
  3. Regulartory Affairs, Sanofi K.K., Tokyo, Japan.

PMID: 34218511 PMCID: PMC8452295 DOI: 10.1002/psp4.12676

Abstract

To characterize and compare various medicines for chronic heart failure (CHF), changes in circulatory physiological parameter during pharmacotherapy were investigated by a model-based meta-analysis (MBMA) of circulatory physiology. The clinical data from 61 studies mostly in patients with heart failure with reduced ejection fraction (HFrEF), reporting changes in heart rate, blood pressure, or ventricular volumes after treatment with carvedilol, metoprolol, bisoprolol, bucindolol, enalapril, aliskiren, or felodipine, were analyzed. Seven cardiac and vasculature function indices were estimated without invasive measurements using models based on appropriate assumptions, and their correlations with the mortality were assessed. Estimated myocardial oxygen consumption, a cardiac load index, correlated excellently with the mortality at 3, 6, and 12 months after treatment initiation, and it explained differences in mortality across the different medications. The analysis based on the present models were reasonably consistent with the hypothesis that the treatment of HFrEF with various medications is due to effectively reducing the cardiac load. Assessment of circulatory physiological parameters by using MBMA would be insightful for quantitative understanding of CHF treatment.

© 2021 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.

References

  1. Lancet. 2003 Jul 5;362(9377):7-13 - PubMed
  2. Ann Intern Med. 2009 Jun 2;150(11):784-94 - PubMed
  3. BMJ. 2013 Jan 16;346:f55 - PubMed
  4. CPT Pharmacometrics Syst Pharmacol. 2021 Sep;10(9):1081-1091 - PubMed
  5. BMC Med. 2020 May 5;18(1):103 - PubMed
  6. Arzneimittelforschung. 1986 Feb;36(2):200-8 - PubMed
  7. J Am Coll Cardiol. 1997 Oct;30(4):992-6 - PubMed
  8. JAMA. 2013 Mar 20;309(11):1125-35 - PubMed
  9. Lancet. 1999 Jun 12;353(9169):2001-7 - PubMed
  10. Lancet. 1999 Jan 2;353(9146):9-13 - PubMed
  11. Am J Physiol. 1998 Feb;274(2):H500-5 - PubMed
  12. Control Clin Trials. 1986 Sep;7(3):177-88 - PubMed
  13. Circulation. 1993 Jan;87(1):59-69 - PubMed
  14. Circulation. 1997 Aug 5;96(3):856-63 - PubMed
  15. J Am Coll Cardiol. 2013 Nov 19;62(21):1977-1985 - PubMed
  16. J Physiol Sci. 2017 Nov;67(6):655-672 - PubMed
  17. Am J Physiol. 1983 Nov;245(5 Pt 1):H773-80 - PubMed
  18. Am J Physiol. 1993 Dec;265(6 Pt 2):H1884-92 - PubMed
  19. J Am Coll Cardiol. 2012 Jan 31;59(5):442-51 - PubMed
  20. N Engl J Med. 1991 Aug 1;325(5):293-302 - PubMed
  21. Circulation. 1992 Aug;86(2):513-21 - PubMed
  22. Am J Physiol. 1979 Mar;236(3):H498-505 - PubMed
  23. Eur Heart J. 2018 Sep 1;39(33):3021-3104 - PubMed
  24. N Engl J Med. 2001 May 31;344(22):1659-67 - PubMed
  25. J Clin Invest. 1995 Mar;95(3):1271-80 - PubMed
  26. Hypertension. 2001 May;37(5):1216-21 - PubMed
  27. Eur J Heart Fail. 2013 Oct;15(10):1082-94 - PubMed
  28. Am J Cardiovasc Drugs. 2001;1(1):3-14 - PubMed
  29. Trends Pharmacol Sci. 2011 Apr;32(4):206-12 - PubMed
  30. J Cardiovasc Pharmacol. 1985;7 Suppl 4:S28-32 - PubMed
  31. Circulation. 2017 Aug 8;136(6):e137-e161 - PubMed
  32. Front Physiol. 2013 Nov 14;4:323 - PubMed
  33. Circulation. 1998 Aug 25;98(8):794-9 - PubMed

Publication Types